


**Figure S1.** Proportions of T and B cells including those expressing combinations of CD39 and CD73 do not differ between concurrent chemotherapy (Cx) or Cetuximab (Ix). (A–G) HNSCC patients from Figure 2 were stratified by treatment (concurrent chemotherapy,  $n = 13$ ; or Cetuximab,  $n = 7$ ) and cell responses presented as fold change from pre-treatment to post-treatment. Data represents groups means  $\pm$  SD; symbols represent individual donors; ns represents not significant; unpaired two-tailed Student's  $t$ -test or Mann-Whitney U test.



**Figure S2.** Treatment modality and human papillomavirus (HPV) status are not associated relapse free survival (RFS). RFS univariate analysis via the log-rank (Mantel-Cox), stratified according to (A) treatment modality ( $n = 27$ ) and (B) HPV status ( $n = 27$ ). No significant differences between groups.